secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001140361-23-051047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q3 2023 revenue $144M, net loss $143M; eplontersen on track for Dec 2023 U.S. approval
--------------------------------------------------------------------------------

- Total revenue $144M (-10% YoY); SPINRAZA royalties $67M flat; R&D revenue $60M down from $87M.
- Operating expenses $287M (+31% YoY); loss from operations $143M vs. $59M loss in Q3 2022.
- Cash and short-term investments $2.2B; reaffirmed 2023 financial guidance.
- Eplontersen regulatory submissions accepted in EU and Canada; potential U.S. approval in Dec 2023.
- Olezarsen Phase 3 Balance study met endpoints: significant triglyceride lowering, reduced pancreatitis attacks; on track for early 2024 filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/0001140361-23-051047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123051047/ef20013902_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-051047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer